← All Dermatologist Certificate Flashcard Decks

Skin Cancer Pathology and Oncology Flashcards

6 cards from real Dermatologist Certificate practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 6 Skin Cancer Pathology and Oncology flashcards as text
  1. What is the most common type of skin cancer in the United States?

    Answer: Basal cell carcinoma (BCC)

    Basal cell carcinoma is the most common human malignancy, accounting for approximately 80% of all non-melanoma skin cancers and affecting millions of Americans annually.

  2. Which histological subtype of basal cell carcinoma carries the highest risk of recurrence and invasion?

    Answer: Morpheaform (sclerosing/infiltrative) BCC

    Morpheaform BCC has indistinct clinical borders with finger-like projections extending well beyond the visible lesion, making it the most aggressive subtype with the highest recurrence rate.

  3. Squamous cell carcinoma arising in a chronic wound or scar is known as which eponymous carcinoma?

    Answer: Marjolin ulcer

    Marjolin ulcer is SCC arising from chronic wounds, burn scars, osteomyelitis sinuses, or other areas of chronic inflammation, typically with an aggressive course and higher metastatic risk.

  4. What feature of melanoma on dermoscopy is most specific for malignancy?

    Answer: Blue-white veil overlying raised areas

    The blue-white veil — an irregular, structureless, ground-glass blue area with overlying white haze — is a dermoscopic feature highly specific for invasive melanoma.

  5. PD-1 checkpoint inhibitors (nivolumab, pembrolizumab) are approved for which stage of melanoma?

    Answer: Advanced/metastatic melanoma and high-risk resected stage III/IV adjuvant therapy

    Anti-PD-1 immunotherapy is approved for unresectable or metastatic melanoma and as adjuvant therapy for high-risk resected stage III and stage IV melanoma to reduce recurrence.

  6. BRAF V600E mutation is found in approximately what percentage of cutaneous melanomas?

    Answer: 50–60% of cutaneous melanomas

    BRAF V600E mutations are present in approximately 50–60% of cutaneous melanomas, making BRAF/MEK inhibitor combination therapy (e.g., dabrafenib/trametinib) applicable to a large proportion of patients.

How this page was made: written with AI tools and published by Nathan Beja, founder of Practice Test Geeks, who is responsible for its content. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

  1. abderm.org — Fees, registration, renewal, test delivery, exam dates, test dates, eligibility, retake fee, retake policy, exam format · verified Oct 2026
  2. pearsonvue.com — Test delivery · verified Oct 2026